Cartesian Therapeutics (RNAC) EV to EBIT (2022)
Cartesian Therapeutics' (RNAC) EV to EBIT was 347.61 for Q4 2022, up 27.7% from the prior quarter.
Powered by 
Analysis
Cartesian Therapeutics (RNAC) EV to EBIT (2022) Analysis & Trends
Dating back to Q1 2022, Cartesian Therapeutics' EV to EBIT record includes 4 quarters.
- Per Business Quant data, the three quarters before Q4 2022 came in at 272.30 (Q3 2022), 219.11 (Q2 2022) and 335.40 (Q1 2022).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,144.36 Bn | 1,112.95 Bn | 19.71 Bn |
| 2 | Johnson & Johnson | 635.36 Bn | 555.22 Bn | 17.30 Bn |
| 3 | AbbVie | 502.79 Bn | 475.90 Bn | 12.70 Bn |
| 4 | Merck | 356.08 Bn | 310.46 Bn | 12.21 Bn |
| 5 | Novartis Ag | 300.87 Bn | 264.86 Bn | 11.24 Bn |
| 6 | Astrazeneca | 264.31 Bn | 237.99 Bn | 12.86 Bn |
| 7 | Amgen | 239.07 Bn | 194.47 Bn | 7.24 Bn |
| 8 | Gilead Sciences | 194.50 Bn | 168.70 Bn | 6.22 Bn |
| 9 | Pfizer | 171.00 Bn | 117.64 Bn | 10.94 Bn |
| 10 | Cartesian Therapeutics | 182.99 Mn | -351.78 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2022 | 347.61 |
| Sep 30, 2022 | 272.30 |
| Jun 30, 2022 | 219.11 |
| Mar 31, 2022 | 335.40 |
API Access
Cartesian Therapeutics EV to EBIT API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ev-to-ebit&ticker=RNAC&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ev-to-ebit", "ticker": "RNAC", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ev-to-ebit&ticker=RNAC&period=max&api_key=YOUR_API_KEY");
const data = await res.json();